BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 12577246)

  • 21. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
    Anné PR; Curran WJ
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
    Anacak Y; Kamer S; Haydaroglu A
    Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
    Burlage FR; Roesink JM; Kampinga HH; Coppes RP; Terhaard C; Langendijk JA; van Luijk P; Stokman MA; Vissink A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):14-22. PubMed ID: 17869018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI; Yannakakis D
    Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
    Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
    Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
    J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
    Boccia R
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
    de Castro G; Federico MH
    Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
    Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
    Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
    Anné PR; Machtay M; Rosenthal DI; Brizel DM; Morrison WH; Irwin DH; Chougule PB; Estopinal NC; Berson A; Curran WJ
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):445-52. PubMed ID: 17141978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
    Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
    Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
    J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
    Koukourakis MI; Simopoulos C; Minopoulos G; Patlakas G; Polychronidis A; Limberis V; Romanides K; Pitiacoudis M; Manolas C
    Clin Cancer Res; 2003 Aug; 9(9):3288-93. PubMed ID: 12960114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
    Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.